# The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma

> **NCT05839275** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 52 (estimated)

## Conditions studied

- High-Risk Localized Soft Tissue Sarcoma

## Interventions

- **DRUG:** Surufatinib
- **DRUG:** Sintilimab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT05839275
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2024-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05839275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05839275, "The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05839275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*